Business Acquisitions Business Acquisitions (Details) (USD $)	3 Months Ended			9 Months Ended		12 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended		9 Months Ended	12 Months Ended		3 Months Ended				3 Months Ended	9 Months Ended		9 Months Ended					12 Months Ended			3 Months Ended			12 Months Ended		3 Months Ended			3 Months Ended			3 Months Ended				3 Months Ended			3 Months Ended			3 Months Ended		12 Months Ended		3 Months Ended		3 Months Ended		12 Months Ended		3 Months Ended		3 Months Ended	12 Months Ended			3 Months Ended		3 Months Ended		3 Months Ended							3 Months Ended	12 Months Ended		0 Months Ended	3 Months Ended		9 Months Ended			0 Months Ended	3 Months Ended		9 Months Ended			0 Months Ended	3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended			3 Months Ended
	Mar. 29, 2014	Dec. 28, 2013	Mar. 30, 2013	Mar. 29, 2014	Mar. 30, 2013	Jun. 29, 2013	Mar. 29, 2014 Velcera, Inc. [Domain]	Mar. 29, 2014 Velcera, Inc. [Domain]	Jun. 29, 2013 Velcera, Inc. [Domain]	Apr. 01, 2013 Velcera, Inc. [Domain]	Mar. 29, 2014 Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Rosemont Pharmaceuticals Ltd. [Domain]	Mar. 30, 2013 Cobrek Pharmaceuticals, Inc. [Domain]	Dec. 28, 2012 Cobrek Pharmaceuticals, Inc. [Domain]	May 29, 2008 Cobrek Pharmaceuticals, Inc. [Domain]	Dec. 18, 2013 Perrigo Company [Member]	Mar. 29, 2014 Elan Corporation [Member]	Mar. 29, 2014 Elan Corporation [Member]	Dec. 18, 2013 Elan Corporation [Member]	Mar. 29, 2014 Elan, Aspen and Fera [Domain]	Mar. 30, 2013 Elan, Aspen and Fera [Domain]	Mar. 29, 2014 Vedants Drug and Fine Chemicals Private Ltd [Member]	Jun. 10, 2013 Vedants Drug and Fine Chemicals Private Ltd [Member]	Aug. 06, 2009 Vedants Drug and Fine Chemicals Private Ltd [Member]	Jun. 29, 2013 Fera Pharmaceuticals, LLC [Domain]	Feb. 18, 2014 Fera Pharmaceuticals, LLC [Domain]	Jun. 17, 2013 Fera Pharmaceuticals, LLC [Domain]	Mar. 29, 2014 Aspen Global Inc. [Domain]	Feb. 28, 2014 Aspen Global Inc. [Domain]	Dec. 28, 2012 Cobrek Pharmaceuticals [Member]	Jun. 29, 2013 Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 Sergeant's Pet Care Products, Inc. [Domain]	Mar. 29, 2014 Distribution And License Agreements [Member] Fera Pharmaceuticals, LLC [Domain]	Jun. 29, 2013 Licensing Agreements [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Licensing Agreements [Member] Velcera, Inc. [Domain]	Mar. 30, 2013 Licensing Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Licensing Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 18, 2014 Licensing Agreements [Member] Fera Pharmaceuticals, LLC [Domain]	Mar. 30, 2013 Exclusive technology agreements [Member] Cobrek Pharmaceuticals [Member]	Jun. 29, 2013 Trademarks and Trade Names [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Trademarks and Trade Names [Member] Velcera, Inc. [Domain]	Feb. 11, 2013 Trademarks and Trade Names [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Mar. 29, 2014 Trademarks and Trade Names [Member] Aspen Global Inc. [Domain]	Feb. 28, 2014 Trademarks and Trade Names [Member] Aspen Global Inc. [Domain]	Oct. 01, 2012 Trademarks and Trade Names [Member] Sergeant's Pet Care Products, Inc. [Domain]	Mar. 29, 2014 Licensing Agreements [Member]	Mar. 29, 2014 Licensing Agreements [Member] Elan Corporation [Member]	Dec. 18, 2013 Licensing Agreements [Member] Elan Corporation [Member]	Mar. 29, 2014 Prialt [Member] Elan Corporation [Member]	Dec. 18, 2013 Prialt [Member] Elan Corporation [Member]	Jun. 29, 2013 favorable supply agreement [Domain] Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 favorable supply agreement [Domain] Sergeant's Pet Care Products, Inc. [Domain]	Jun. 29, 2013 Customer Relationships [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Customer Relationships [Member] Velcera, Inc. [Domain]	Mar. 29, 2014 Customer Relationships [Member] Aspen Global Inc. [Domain]	Feb. 28, 2014 Customer Relationships [Member] Aspen Global Inc. [Domain]	Jun. 29, 2013 Customer Relationships [Member] Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 Customer Relationships [Member] Sergeant's Pet Care Products, Inc. [Domain]	Mar. 30, 2013 Developed Technology Rights [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Developed Technology Rights [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Developed Technology Rights [Member] Fera Pharmaceuticals, LLC [Domain]	Jun. 29, 2013 Developed Technology Rights [Member] Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 Developed Technology Rights [Member] Sergeant's Pet Care Products, Inc. [Domain]	Feb. 11, 2013 In Process Research and Development [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Noncompete Agreements [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Noncompete Agreements [Member] Velcera, Inc. [Domain]	Mar. 30, 2013 Noncompete Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Noncompete Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Mar. 29, 2014 Noncompete Agreements [Member] Aspen Global Inc. [Domain]	Feb. 28, 2014 Noncompete Agreements [Member] Aspen Global Inc. [Domain]	Oct. 01, 2012 Noncompete Agreements [Member] Sergeant's Pet Care Products, Inc. [Domain]	Apr. 01, 2013 Purchase Price Allocation Adjustments [Member] Velcera, Inc. [Domain]	Oct. 01, 2012 Purchase Price Allocation Adjustments [Member] Sergeant's Pet Care Products, Inc. [Domain]	Dec. 28, 2012 Final Valuation [Domain] Cobrek Pharmaceuticals [Member]	Oct. 01, 2012 Final Valuation [Domain] Sergeant's Pet Care Products, Inc. [Domain]	Mar. 29, 2014 Minimum [Member] Licensing Agreements [Member]	Jun. 29, 2013 Minimum [Member] Noncompete Agreements [Member] Sergeant's Pet Care Products, Inc. [Domain]	Jun. 29, 2013 Maximum [Member] Noncompete Agreements [Member] Sergeant's Pet Care Products, Inc. [Domain]	Dec. 28, 2013 Consumer Healthcare [Member]	Mar. 29, 2014 Consumer Healthcare [Member]	Mar. 30, 2013 Consumer Healthcare [Member]	Mar. 29, 2014 Consumer Healthcare [Member]	Mar. 30, 2013 Consumer Healthcare [Member]	Jun. 29, 2013 Consumer Healthcare [Member]	Dec. 28, 2013 Rx Pharmaceuticals [Member]	Mar. 29, 2014 Rx Pharmaceuticals [Member]	Mar. 30, 2013 Rx Pharmaceuticals [Member]	Mar. 29, 2014 Rx Pharmaceuticals [Member]	Mar. 30, 2013 Rx Pharmaceuticals [Member]	Jun. 29, 2013 Rx Pharmaceuticals [Member]	Dec. 28, 2013 Nutritionals [Member]	Mar. 29, 2014 Nutritionals [Member]	Mar. 30, 2013 Nutritionals [Member]	Mar. 29, 2014 Nutritionals [Member]	Mar. 30, 2013 Nutritionals [Member]	Jun. 29, 2013 Nutritionals [Member]	Mar. 29, 2014 Specialty Sciences [Member]	Mar. 30, 2013 Specialty Sciences [Member]	Mar. 29, 2014 Specialty Sciences [Member]	Mar. 30, 2013 Specialty Sciences [Member]	Jun. 29, 2013 Specialty Sciences [Member]	Mar. 29, 2014 Trench 1 - $0 - $2 billion in sales [Member] Licensing Agreements [Member]	Mar. 29, 2014 Trench 1 - $0 - $2 billion in sales [Member] Maximum [Member] Licensing Agreements [Member]	Mar. 29, 2014 Trench 2 - over $2 billion in sales [Member] Licensing Agreements [Member]	Mar. 29, 2014 Trench 2 - over $2 billion in sales [Member] Minimum [Member] Licensing Agreements [Member]	Mar. 29, 2014 Trench 1 - up to $12.5 million in sales [Member] Prialt [Member]	Mar. 29, 2014 Trench 1 - up to $12.5 million in sales [Member] Minimum [Member] Prialt [Member]	Mar. 29, 2014 Trench 1 - up to $12.5 million in sales [Member] Maximum [Member] Prialt [Member]	Mar. 29, 2014 Trench 2 - $12.5 - $20 million in sales [Member] Prialt [Member]	Mar. 29, 2014 Trench 2 - $12.5 - $20 million in sales [Member] Minimum [Member] Prialt [Member]	Mar. 29, 2014 Trench 2 - $12.5 - $20 million in sales [Member] Maximum [Member] Prialt [Member]	Mar. 29, 2014 Trench 3 - $20 - $35 million in sales [Member] Prialt [Member]	Mar. 29, 2014 Trench 3 - $20 - $35 million in sales [Member] Minimum [Member] Prialt [Member]	Mar. 29, 2014 Trench 3 - $20 - $35 million in sales [Member] Maximum [Member] Prialt [Member]	Mar. 29, 2014 Trench 4 - $35 - $50 million in sales [Member] Prialt [Member]	Mar. 29, 2014 Trench 4 - $35 - $50 million in sales [Member] Minimum [Member] Prialt [Member]	Mar. 29, 2014 Trench 4 - $35 - $50 million in sales [Member] Maximum [Member] Prialt [Member]	Mar. 29, 2014 Trench 5 - Over $50 million in sales [Member] Prialt [Member]	Mar. 29, 2014 Trench 5 - Over $50 million in sales [Member] Minimum [Member] Prialt [Member]
Business Acquisition [Line Items]
Accrued liabilities				$ 8,800,000	$ 10,100,000													$ 8,700,000
Increase (Decrease) in Other Accrued Liabilities																		3,700,000
Tax expense due to payout of unvested shares																		(500,000)
Goodwill, Period Increase (Decrease)																		11,900,000
Total consideration / Net assets acquired										175,100,000			282,900,000							9,451,900,000								110,600,000					285,000,000																																										51,500,000	285,000,000
Business Acquisition, Cash Exchange per share																				$ 6.25
Exchange ratio per share																				0.07636
Business Acquisition, Percentage of Voting Interests Acquired															81.50%		71.00%			29.00%				15.00%
Total acquisition-related costs	0								1,100,000			2,000,000							284,900,000							100,000			27,000			2,000,000
Administration expense	81,100,000		62,600,000	314,200,000	176,000,000														108,900,000
Interest, net	26,200,000		16,100,000	77,300,000	47,200,000														10,000,000
Other expense, net	1,700,000		800,000	6,800,000	800,000														200,000
Loss on extinguishment of debt	0	165,800,000	0	165,800,000	0														165,800,000
Total value of Perrigo shares issued to Elan shareholders																				6,117,200,000
Cash consideration paid at $6.25 per Elan share																	0.01			3,223,200,000
Elan shares outstanding as of December 18, 2013																				515,700,000
Total Company shares issued to acquired company shareholders																				39,400,000
Perrigo per share value at transaction close on December 18, 2013																				$ 155.34
Cash consideration paid for vested Elan stock options and share awards																				111,500,000
Cash consideration paid for unvested Elan stock options and awards																				16,100,000
Cash and cash equivalents										18,900,000			2,100,000							1,807,300,000
Investment securities (Current and noncurrent)																				100,000,000
Accounts receivable										6,300,000			10,600,000							44,200,000																																																								19,700,000
Prepaids and other current assets																				27,100,000
Property and equipment										600,000			13,100,000							9,200,000																																																								25,400,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent										7,900,000			200,000																																																														3,600,000	1,500,000
Goodwill	3,207,400,000			3,207,400,000		1,089,300,000				62,500,000			147,000,000							2,088,500,000								2,800,000		4,600,000																																												12,000,000	15,300,000	80,200,000					712,000,000		712,000,000		279,900,000		719,400,000		719,400,000		385,500,000		423,200,000		423,200,000		331,700,000	1,257,200,000		1,257,200,000		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investments																				66,300,000
Definite-lived intangible assets										135,300,000			148,200,000							6,111,000,000								107,000,000		46,400,000			135,400,000						17,000,000						34,800,000												9,800,000														1,800,000		3,000,000		51,100,000	135,400,000
Other non-current assets										400,000			800,000							27,100,000																																																							300,000	3,000,000
Total assets acquired										241,600,000			331,600,000							10,280,700,000								111,100,000		53,700,000																																													70,300,000	302,900,000
Business Combination, Customer Related Accruals and Allowances																												500,000
Accounts payable										6,500,000			2,600,000							2,000,000																																																								13,700,000
Accrued expenses										4,800,000			7,600,000							93,500,000																																																								4,200,000
Deferred tax liabilities										48,200,000			36,000,000							702,200,000																																																							18,800,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other										7,000,000			2,500,000
Other non-current liabilities																				31,100,000
Total liabilities assumed										66,500,000			48,700,000							828,800,000								500,000																																															18,800,000	17,900,000
Amount of goodwill allocated to other business segments																				831,300,000
Goodwill, Acquired During Period				2,093,100,000																																																																												423,700,000			428,300,000			316,100,000			316,100,000			91,500,000			91,500,000					1,257,200,000
Royalty rate as a percent of net sales year one																																															12.00%
Write-off of in process research and development	0		0	6,000,000	0						2,000,000
Net sales	1,004,200,000		919,800,000	2,916,600,000	2,572,600,000																65,500,000																																																								0				537,300,000	536,800,000	1,612,100,000	1,526,500,000			223,400,000	189,400,000	673,600,000	514,900,000			137,800,000	133,300,000	406,600,000	358,700,000		53,400,000	0	60,800,000	0			2,000,000,000		2,000,001,000		0	12,500,000		12,500,000	20,000,000		20,000,000	35,000,000		35,000,000	50,000,000		50,000,000
Royalty rate as a percent of net sales																																																																																																											7.00%			10.25%			17.50%			13.50%			10.25%
Royalty rate as a percent of net sales year two																																																																																																							18.00%		25.00%
Other intangible assets acquired										135,300,000			148,200,000																							116,000,000		3,600,000				7,600,000	17,300,000			33,000,000			6,100,000,000		11,000,000		25,000,000		8,700,000				10,000,000		114,600,000			66,100,000	11,200,000		3,000,000		1,500,000			1,300,000
Acquired intangible assets, average estimated useful lives (in years)																																		15 years	10 years		14 years			12 years	25 years			25 years				20 years		10 years		7 years		20 years		15 years		20 years		7 years		15 years	10 years			3 years		3 years		5 years								1 year	3 years
Operating Income (Loss)	103,300,000		178,600,000	369,500,000	499,000,000																(70,700,000)																																																												84,400,000	95,900,000	263,800,000	261,300,000			77,000,000	73,400,000	260,500,000	206,000,000			7,300,000	7,000,000	28,300,000	18,000,000		(54,500,000)	0	(73,500,000)	0
Restructuring	19,500,000		0	36,500,000	0	2,900,000	700,000												32,000,000
Net sales																					3,048,400,000	2,618,100,000
Net income (loss)																					119,400,000	(390,700,000)
Payment for Business Combination, Cash Payment										156,200,000					42,000,000								7,200,000				17,300,000	88,400,000		53,700,000
Contingent consideration																												22,200,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage																18.50%									85.00%
Investment Owned, at Cost																12,600,000									11,500,000
Inventory										9,700,000			9,600,000														300,000	1,300,000		2,700,000																																														37,700,000
Inventory Fair Value Adjustment												3,200,000																				7,700,000
Fixed Assets Fair Value Adjustment												4,900,000																				6,100,000
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value																															9,500,000
Loss on sales of investments	12,700,000		1,600,000	12,700,000	4,700,000									3,000,000
Business Combination, Integration Related Costs									2,700,000					1,500,000
Restructuring Reserve, Period Increase (Decrease)								1,400,000
Intangible assets amortization expense	$ 107,400,000		$ 24,600,000	$ 181,100,000	$ 65,000,000														$ 85,000,000																																																														$ 5,300,000	$ 5,000,000	$ 15,900,000	$ 12,200,000			$ 17,500,000	$ 11,400,000	$ 55,200,000	$ 28,200,000			$ 7,300,000	$ 7,300,000	$ 22,100,000	$ 21,900,000		$ 76,400,000	$ 0	$ 85,000,000	$ 0